



May 2026

ACR Update

The ACR team celebrating enrolling their first CAPRI patient with Capri Suns!



Study Spotlight

Eyepoint EYP-1901-304 CAPRI

A phase 3 study evaluating a new treatment pathway for patients with Diabetic Macular Edema (DME) versus standard of care Eylea. An insert supplies a consistent daily dose of medication and has the potential to reduce treatment burden.

[Click here for more information](#)



Enrolling Trials

(Click on each study name for more info!)

Dry Age-Related Macular Degeneration (AMD)

[Sanofi DF118231](#)

[Character Biosciences CTX114](#)

Wet Age-Related Macular Degeneration (AMD)

[DF117940 Sanofi](#)

[Hoffman-La Roche GR40549](#)

[4DMT 4D-150-C004 4FRONT-2](#)

[Abbvie ABBV-RGX-314](#)

[Adverum ADVM-022-13 AQUARIUS](#)

[Genentech ML43000 Belvedere](#)

Diabetic Macular Edema (DME)

[Genentech GR46431](#)

[Boehringer-Ingelheim 1485-0018 Thulite \(oral agent\)](#)

[Eyepoint EYP-1901-304 CAPRI](#)

Study Spotlight

Genentech ML43000 Belvedere

A phase 4 study evaluating an FDA-approved implant, Susvimo, in patients with Wet Age-related Macular Degeneration (Wet AMD). Typical treatment plans for Wet AMD require injections every 4-16 weeks. In this study, the implant is refilled every 24 weeks.

[Click here for more information](#)